Form 4: Viridian Therapeutics Director Arlene Morris Acquires Stock Options

Director Arlene Morris acquired 21,000 stock options in Viridian Therapeutics, Inc. on June 26, 2024, according to a Form 4 filing with the SEC.

Summary

• Arlene Morris, a director of Viridian Therapeutics, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on June 26, 2024, where Morris acquired 21,000 stock options.
• These options have an exercise price of $12.31.
• The options vest fully on the earlier of June 26, 2025, or the Issuer's 2025 annual meeting of stockholders, contingent upon continued service on the Board.
• Following the reported transaction, Morris directly owns 21,000 derivative securities.
• A Power of Attorney was executed on June 26, 2024, granting Thomas Beetham, Seth Harmon, and Jennifer Tousignant the authority to execute Forms 3, 4, and 5 on Morris's behalf.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard transaction (stock option grant) with no particularly positive or negative implications.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continued service, suggesting an expectation of ongoing involvement by the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded biotechnology companies.
• The size and vesting schedule of the options are generally in line with industry practices for companies of similar size and stage of development as Viridian Therapeutics.
• Comparing Viridian's option grants to those of companies like Alnylam Pharmaceuticals or Sarepta Therapeutics, which are also in the biotechnology space, would provide a more detailed benchmark.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates